These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

986 related articles for article (PubMed ID: 23324188)

  • 41. Reproductive function after treatment of ovarian germ cell malignancy.
    Anita AN; Rushdan MN
    Med J Malaysia; 2012 Feb; 67(1):71-6. PubMed ID: 22582552
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival.
    Bristow RE; Zerbe MJ; Rosenshein NB; Grumbine FC; Montz FJ
    Gynecol Oncol; 2000 Aug; 78(2):85-91. PubMed ID: 10926785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary.
    Tangir J; Zelterman D; Ma W; Schwartz PE
    Obstet Gynecol; 2003 Feb; 101(2):251-7. PubMed ID: 12576247
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Surgical treatment and prognostic analysis of 109 patients with primary esophageal small cell carcinoma].
    Zhang BH; Yang WJ; Zhao L; He J; Wang YG; Zhang HT
    Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):698-702. PubMed ID: 23159085
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients.
    Peccatori F; Bonazzi C; Chiari S; Landoni F; Colombo N; Mangioni C
    Obstet Gynecol; 1995 Sep; 86(3):367-72. PubMed ID: 7651644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
    Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
    Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
    Kang H; Kim TJ; Kim WY; Choi CH; Lee JW; Kim BG; Bae DS
    Gynecol Oncol; 2008 Oct; 111(1):106-10. PubMed ID: 18656249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
    van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
    Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
    Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
    Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Childhood malignant ovarian germ cell tumors: a monoinstitutional experience.
    Terenziani M; Massimino M; Casanova M; Cefalo G; Ferrari A; Luksch R; Spreafico F; Polastri D; Fontanelli R; Piva L; Fossati-Bellani F
    Gynecol Oncol; 2001 Jun; 81(3):436-40. PubMed ID: 11371135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Malignant ovarian germ cell tumours: a trial of 36 cases].
    Gueye A; Narducci F; Baranzelli MC; Collinet P; Farine O; Fournier C; Vinatier D; Leblanc E
    Gynecol Obstet Fertil; 2007 May; 35(5):406-19. PubMed ID: 17350873
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer?
    Kim JJ; Park JY; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
    Acta Obstet Gynecol Scand; 2010 May; 89(5):623-8. PubMed ID: 20423275
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Uterine papillary serous carcinoma: patterns of failure and survival.
    Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
    Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical management of malignant ovarian germ cell tumors: A 26-year experience in a tertiary care institution.
    Hu T; Fang Y; Sun Q; Zhao H; Ma D; Zhu T; Wang C
    Surg Oncol; 2019 Dec; 31():8-13. PubMed ID: 31446304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
    Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma].
    Zang R; Zhang Z; Cai S
    Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary.
    Culine S; Kattan J; Lhomme C; Duvillard P; Michel G; Castaigne D; Leclere J; Pico J; Droz JP
    Gynecol Oncol; 1994 Jul; 54(1):47-53. PubMed ID: 7517380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.